BioPharma Today

Coming In Thursday's "The Pink Sheet" DAILY - Celsion Begins Transition To A Commerical Stage Company

With pivotal Phase III data for lead candidate ThermoDox about a year away, Celsion is preparing to transition from a clinical-stage company into a commercial operation. The biotech, currently based in Columbia, Md., will be moving to New Jersey early next quarter as it prepares to double its staff over the next year.

Latest News From "The Pink Sheet" DAILY - Selecta To Combine Forces With SAIC On Malaria Work

Selecta To Perform Preclinical Malaria Vaccine Work For SAIC

Biotech will combine its SVP platform technology with a SAIC-developed antigen to try to find the key to treating malaria.   read more

Editors' Picks from the World Press

Pipeline/RD News

• Study: Pfizer's Inspra cuts risk of heart failure in diabetics
• Eisai's perampanel helps reduce seizures in Phase III trial
• Study: Astellas' anti-coagulant appears risky for heart patients

India Moves To Close Traditional Medicine Colleges Not Operating According To Standards

Article preview from "PharmAsia News"-  August 30, 2011

NEW DELHI - As part of a comprehensive overhaul, India's Department of Ayush, which deals with the Indian traditional system of medicine, locally known as ayurveda, has decided to close 180 ayurveda-based medical colleges that have not been operating according to prescribed standards.

Coming In Wednesday's "The Pink Sheet" DAILY - Ariad Executive Discusses Regulatory Approval Process

Ariad’s chief scientific officer talks to “The Pink Sheet” DAILY about the accelerated approval process in the wake of regulatory changes and how it will impact the industry.

Ipsen extends its deal with Inspiration Biopharmaceuticals, appoints new CFO and updates its sales forecast.

Latest News From "The Pink Sheet" DAILY - FDA Seeks More Clinical Data On Novartis' Gout Drug Ilaris

Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

Editors' Picks From The World Press

Pipeline/RD News

• Scientists work on a drug for type 1 diabetes

Coming In Tuesday's "The Pink Sheet" DAILY - How BMS/Pfizer's Apixaban Stacks up To The Competition

Mortality benefit data could give Bristol-Myers Squibb and Pfizer’s apixaban a leg up over other novel oral anticoagulants.

Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris

Article preview from "The Pink Sheet"-  August 29, 2011

Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.

Latest News From "The Pink Sheet" DAILY - Pfizer Wins FDA Approval For Xalkori

Pfizer's Crizotinib Eases Past FDA With Targeted Population

Xalkori is the second targeted oncologic approved with a companion diagnostic this year, FDA says, following Roche's Zelboraf just 10 days prior. read more